Science & Enterprise subscription

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn

Affiliations

Biotech, Cancer Center Partner on T-Cell Research

A developer of cancer diagnostics and treatments is collaborating with Moffitt Cancer Center to advance therapies for ovarian cancer with T-cells from the immune system. . . . → Read More: Biotech, Cancer Center Partner on T-Cell Research

Bayer Acquiring Therapeutic Peptides in $1.1B+ Deal

Bayer AG, the global drug maker and agricultural chemical company, is partnering with a Japanese biologics enterprise to discover a series of peptides for therapies. . . . → Read More: Bayer Acquiring Therapeutic Peptides in $1.1B+ Deal

Biotech Licenses Mayo Clinic Microbiome Research

A biotechnology company developing therapies with specialized gut microbes is licensing research from the Mayo Clinic on these microbes’ effects with autoimmune diseases. . . . → Read More: Biotech Licenses Mayo Clinic Microbiome Research

Alliance Exploring Microbiome on Cancer Immunotherapy

A biotechnology company and two research institutes are collaborating on a study of a proposed cancer treatment that targets the microbiome, communities of bacteria in the human body. . . . → Read More: Alliance Exploring Microbiome on Cancer Immunotherapy

Zymeworks, Janssen in $1.45B Antibody Licensing Deal

Janssen Biotech, a division of drug maker Johnson & Johnson, is acquiring technologies that make it possible to create synthetic antibodies that hit multiple targets. . . . → Read More: Zymeworks, Janssen in $1.45B Antibody Licensing Deal

Sanofi Acquires Multiple Sclerosis Drug in $800M Deal

Drug maker Sanofi is licensing a drug candidate from Principia Biopharma Inc. designed to treat multiple sclerosis, an autoimmune condition affecting the brain and nervous system. . . . → Read More: Sanofi Acquires Multiple Sclerosis Drug in $800M Deal

New Drug Shown to Reduce Depressive Behaviors

A new type of treatment for depression that works differently from most other anti-depressive drugs was shown in lab mice to reduce depression-like behaviors. . . . → Read More: New Drug Shown to Reduce Depressive Behaviors

Start-Up Formed to Develop Non-Opioid Pain Drugs

A new enterprise is being formed to develop non-addictive drugs for chronic pain that use different biochemical processes than opioid pain relievers. . . . → Read More: Start-Up Formed to Develop Non-Opioid Pain Drugs

RNA Meds Companies Partner on Human, Animal Vaccines

Synthetic Genomics Inc. and Arcturus Therapeutics Inc. are collaborating on longer-lasting and more robust RNA therapies and vaccines for humans and animals. . . . → Read More: RNA Meds Companies Partner on Human, Animal Vaccines

Univ. Lab, Company Broaden Bacterial Vaccine Impact

Researchers from University at Buffalo and a campus spin-off enterprise devised a way to expand the scope of anti-bacterial vaccines, as shown in tests with lab animals. . . . → Read More: Univ. Lab, Company Broaden Bacterial Vaccine Impact